Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

512 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
CD46-Targeted Theranostics for PET and 225Ac-Radiopharmaceutical Therapy of Multiple Myeloma.
Wadhwa A, Wang S, Patiño-Escobar B, Bidkar AP, Bobba KN, Chan E, Meher N, Bidlingmaier S, Su Y, Dhrona S, Geng H, Sarin V, VanBrocklin HF, Wilson DM, He J, Zhang L, Steri V, Wong SW, Martin TG, Seo Y, Liu B, Wiita AP, Flavell RR. Wadhwa A, et al. Among authors: wong sw. Clin Cancer Res. 2024 Mar 1;30(5):1009-1021. doi: 10.1158/1078-0432.CCR-23-2130. Clin Cancer Res. 2024. PMID: 38109209 Free PMC article.
Proteasome inhibitor-induced modulation reveals the spliceosome as a specific therapeutic vulnerability in multiple myeloma.
Huang HH, Ferguson ID, Thornton AM, Bastola P, Lam C, Lin YT, Choudhry P, Mariano MC, Marcoulis MD, Teo CF, Malato J, Phojanakong PJ, Martin TG 3rd, Wolf JL, Wong SW, Shah N, Hann B, Brooks AN, Wiita AP. Huang HH, et al. Among authors: wong sw. Nat Commun. 2020 Apr 22;11(1):1931. doi: 10.1038/s41467-020-15521-4. Nat Commun. 2020. PMID: 32321912 Free PMC article.
CRISPR-based screens uncover determinants of immunotherapy response in multiple myeloma.
Ramkumar P, Abarientos AB, Tian R, Seyler M, Leong JT, Chen M, Choudhry P, Hechler T, Shah N, Wong SW, Martin TG, Wolf JL, Roybal KT, Pahl A, Taunton J, Wiita AP, Kampmann M. Ramkumar P, et al. Among authors: wong sw. Blood Adv. 2020 Jul 14;4(13):2899-2911. doi: 10.1182/bloodadvances.2019001346. Blood Adv. 2020. PMID: 32589729 Free PMC article.
Phase 1b trial of isatuximab, an anti-CD38 monoclonal antibody, in combination with carfilzomib as treatment of relapsed/refractory multiple myeloma.
Martin TG, Shah N, Richter J, Vesole DH, Wong SW, Huang CY, Madduri D, Jagannath S, Siegel DS, Biran N, Wolf JL, Parekh S, Cho HJ, Munster P, Richard S, Ziti-Ljajic S, Chari A. Martin TG, et al. Among authors: wong sw. Cancer. 2021 Jun 1;127(11):1816-1826. doi: 10.1002/cncr.33448. Epub 2021 Mar 18. Cancer. 2021. PMID: 33735504 Free PMC article. Clinical Trial.
512 results